Plus Therapeutics 2025 net loss widens
Overview
U.S. radiopharmaceutical developer reported 2025 net loss widened to $22.4 mln
Operating loss for 2025 widened
Outlook
Company expects R&D expenditures to increase in 2026 due to expanded clinical trials and manufacturing
Result Drivers
CNSIDE TEAM EXPANSION - Co said higher operating loss was mainly due to expansion of CNSide operations team
DERIVATIVE INSTRUMENTS - Co said change in net loss was primarily due to change in fair value of derivative instruments from Q1 2025 financings
Company press release: ID:nGNXbzwtlv
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income |
| -$22.39 mln |
|
FY Operating Expenses |
| $20.51 mln |
|
FY Operating Income |
| -$15.30 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Plus Therapeutics Inc is $2.00, about 550% above its March 11 closing price of $0.31
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
